2021
Cachexia and bladder cancer: clinical impact and management
Lokeshwar SD, Press BH, Nie J, Klaassen Z, Kenney PA, Leapman MS. Cachexia and bladder cancer: clinical impact and management. Current Opinion In Supportive And Palliative Care 2021, 15: 260-265. PMID: 34698663, DOI: 10.1097/spc.0000000000000580.Peer-Reviewed Original ResearchConceptsRadical cystectomyBladder cancerPharmacological agentsManagement of cachexiaNovel pharmaceutical agentsPostoperative complicationsWorse survivalMultidisciplinary managementClinical outcomesHypercatabolic statePalliative carePoor outcomeClinical trialsNutritional supplementationBCa patientsClinical impactPhysical therapyCachexiaRadiation therapyHuman studiesPatientsTherapeutic outcomesNutritional deficienciesNutritional supplementsTumor microenvironmentAccess to Urologic Care at Urgent Care Centers
Hsiang WR, Yousman L, Kim D, Cavallo JA, Kenney PA, Motamedinia P, Breyer B, Leapman MS. Access to Urologic Care at Urgent Care Centers. Urology 2021, 156: 124-128. PMID: 34181971, DOI: 10.1016/j.urology.2021.06.009.Peer-Reviewed Original ResearchConceptsUrgent care centersUrologic careCare centerCommercial insuranceMultivariable logistic regression analysisPrimary study endpointCross-sectional studyFacility-level characteristicsLogistic regression analysisMedicaid expansion statesLogistic regression modelsState Medicaid expansionsStudy endpointMedicaid insuranceCommercial patientsEmergency departmentReferral ratesPatient insuranceMedicaid patientsUrologic conditionsUrologic emergencyGreater oddsPatientsTriage ratesClinical settingChange in facility-level share of Medicaid patients with cancer following implementation of the affordable care act.
Buck M, Demkowicz P, Nie J, Marks V, Salazar M, Kenney P, Boffa D, Leapman M. Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act. Journal Of Clinical Oncology 2021, 39: e18543-e18543. DOI: 10.1200/jco.2021.39.15_suppl.e18543.Peer-Reviewed Original ResearchProportion of MedicaidAffordable Care ActMedicaid patientsMedicaid expansionFacility-level changesFacility-level policiesNational Cancer DatabasePrimary study endpointProportion of patientsInsurance coverageMultivariable logistic regressionExpansion statesCare ActFacility-level factorsMedicaid expansion statesNon-expansion statesAdult patientsStudy endpointAdjusted differenceCancer DatabaseMedicaid populationEligible facilitiesPatientsCancerLogistic regressionAccessibility of Telehealth services for cancer care at cancer hospital in the United States.
Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Kenney P, Leapman M. Accessibility of Telehealth services for cancer care at cancer hospital in the United States. Journal Of Clinical Oncology 2021, 39: 6535-6535. DOI: 10.1200/jco.2021.39.15_suppl.6535.Peer-Reviewed Original ResearchMultivariable logistic regressionTelehealth servicesCancer typesTelehealth accessTelehealth availabilityNew patientsLogistic regressionCommunity cancer programsNational cross-sectional dataMedicaid Services databaseCare patientsHospital variationCancer HospitalCancer careCancer programsHospital characteristicsCancer sitesBreast cancerMajor cancersAmerican Hospital AssociationPatientsService databaseSkin cancerCancerHospitalAccess to cancer care for Medicaid patients at cancer hospitals in the United States.
Marks V, Hsiang W, Nie J, Buck M, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Kenney P, Leapman M. Access to cancer care for Medicaid patients at cancer hospitals in the United States. Journal Of Clinical Oncology 2021, 39: 6548-6548. DOI: 10.1200/jco.2021.39.15_suppl.6548.Peer-Reviewed Original ResearchMultivariable logistic regressionCancer careAffordable Care ActCancer typesMedicaid acceptanceMedicaid patientsSkin cancerComprehensive community cancer centerLogistic regressionFacility-level differencesCommunity cancer centerBreast cancer careHospital-level variationHospital registry dataFacility-level characteristicsMedicaid Services dataMedicaid accessUnivariable statisticsCancer HospitalCancer CenterRegistry dataAmerican Hospital AssociationNew diagnosisPatientsHospital
2020
Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma
Hsiang WR, Kenney PA, Leapman MS. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Current Oncology Reports 2020, 22: 35. PMID: 32170461, DOI: 10.1007/s11912-020-0895-y.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaSystemic therapyRenal cell carcinomaCytoreductive nephrectomySurgical therapyCell carcinomaManagement of mRCCPoor-risk metastatic renal cell carcinomaInitial systemic therapyReviewThe treatment landscapeTargeted therapy eraUpfront cytoreductive nephrectomyViable treatment approachSequence of surgeryTherapy eraTreatment landscapeUnselected patientsSurgical managementSummaryRecent evidenceRecent FindingsOneTreatment approachesNephrectomyTherapyOptimal rolePatients
2019
PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER
Javier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.Peer-Reviewed Original Research
2017
PD04-09 SHOULD PATIENTS WITH METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA UNDERGO CYTOREDUCTIVE NEPHRECTOMY?
Keskin S, Petros F, Yu K, Aboshady Y, Borregales L, Kenney P, Matin S, Karam J, Wood C. PD04-09 SHOULD PATIENTS WITH METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA UNDERGO CYTOREDUCTIVE NEPHRECTOMY? Journal Of Urology 2017, 197: e65-e66. DOI: 10.1016/j.juro.2017.02.228.Peer-Reviewed Original Research
2014
1042 Predictors of occult lymph node metastases in patients with locally advanced renal cell carcinoma: Who should have a lymph node dissection?
Babaian K, Kenney P, Karam J, Wood C. 1042 Predictors of occult lymph node metastases in patients with locally advanced renal cell carcinoma: Who should have a lymph node dissection? European Urology Open Science 2014, 13: e1042. DOI: 10.1016/s1569-9056(14)61024-1.Peer-Reviewed Original ResearchMP64-03 PREDICTORS OF OCCULT LYMPH NODE METASTASES IN PATIENTS WITH RENAL CELL CARCINOMA: WHO SHOULD UNDERGO A LYMPH NODE DISSECTION?
Babaian K, Kenney P, Kim D, Qiao W, Karam J, Wood C. MP64-03 PREDICTORS OF OCCULT LYMPH NODE METASTASES IN PATIENTS WITH RENAL CELL CARCINOMA: WHO SHOULD UNDERGO A LYMPH NODE DISSECTION? Journal Of Urology 2014, 191: e701. DOI: 10.1016/j.juro.2014.02.1920.Peer-Reviewed Original Research
2013
1906 PREOPERATIVE PULMONARY EMBOLISM DOES NOT PREDICT POOR POSTSURGICAL OUTCOMES IN RCC PATIENTS WITH VENOUS THROMBUS
Abel E, Wood C, Eickstaedt N, Fang J, Kenney P, Bagrodia A, Ramirez D, Gayed B, Downs T, Youssef R, Odom C, Sagalowsky A, Margulis V. 1906 PREOPERATIVE PULMONARY EMBOLISM DOES NOT PREDICT POOR POSTSURGICAL OUTCOMES IN RCC PATIENTS WITH VENOUS THROMBUS. Journal Of Urology 2013, 189: e781. DOI: 10.1016/j.juro.2013.02.2325.Peer-Reviewed Original Research1073 CLINICAL PREDICTORS FOR THE DEVELOPMENT OF PULMONARY METASTASES AMONG RCC PATIENTS WITH INDETERMINATE PULMONARY NODULES
Kenney P, Karam J, Levey R, Nogueras-Gonzalez G, Matin S, Tamboli P, Tannir N, Wood C. 1073 CLINICAL PREDICTORS FOR THE DEVELOPMENT OF PULMONARY METASTASES AMONG RCC PATIENTS WITH INDETERMINATE PULMONARY NODULES. Journal Of Urology 2013, 189: e440. DOI: 10.1016/j.juro.2013.02.662.Peer-Reviewed Original Research
2012
Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma
Kenney PA, Wood CG. Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma. Urologic Clinics Of North America 2012, 39: 211-231. PMID: 22487764, DOI: 10.1016/j.ucl.2012.01.005.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalCarcinoma, Renal CellChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansImmunotherapyKidney NeoplasmsMaleNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm StagingNephrectomyPrognosisRadiotherapy, AdjuvantRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsRenal cell carcinomaSystemic therapyCell carcinomaMetastatic renal cell carcinomaAdvanced nonmetastatic diseaseUpfront cytoreductive nephrectomyIntegration of surgeryCytoreductive nephrectomyCytoreductive surgeryNeoadjuvant therapyNonmetastatic diseaseAdjuvant therapyMetastatic diseaseAppropriate patientsTherapySurgeryDiseaseCurrent roleNephrectomyFurther studiesCarcinomaPotential benefitsPatientsTrialsHIGHER PERIOPERATIVE MORBIDITY AND IN‐HOSPITAL MORTALITY IN PATIENTS WITH END‐STAGE RENAL DISEASE UNDERGOING NEPHRECTOMY FOR NON‐METASTATIC KIDNEY CANCER: A POPULATION‐BASED ANALYSIS
Kenney PA, Karam JA. HIGHER PERIOPERATIVE MORBIDITY AND IN‐HOSPITAL MORTALITY IN PATIENTS WITH END‐STAGE RENAL DISEASE UNDERGOING NEPHRECTOMY FOR NON‐METASTATIC KIDNEY CANCER: A POPULATION‐BASED ANALYSIS. BJU International 2012, 110: e191-e191. PMID: 22321381, DOI: 10.1111/j.1464-410x.2012.11018.x.Peer-Reviewed Original Research